Indian Bulk Drug Industry Insight 2007

Summary

Indian bulk drugs market in 2006 was about US$3.29 billion, witnessing a growth of 19% over 2005 at CAGR of 18.81% in the last six years. India ranks 4th in terms of volume, among the top 15 drug manufacturing countries worldwide. Indian companies have the distinction of developing cost-effective technologies for manufacturing bulk drugs and intermediates, conforming to global standards. India has over 80 US FDA approved plants, the second highest in the world.

Indian bulk drug market is fragmented with top 10 companies contributing 44% of the market and about 1,323 companies accounting for the balance 56%. Nearly 70% of the bulk drugs, manufactured are exported to more than 50 countries. Contract manufacturing in India in 2006 was USD658.6 million, registering a growth of 48% over previous year. Indian companies have filed 408 DMF's during 2006 out of a total 704. By 2010, Indian bulk drugs market is projected to grow to about US$6.54 billion and contract manufacturing to USD1.5billion.

• This report discusses in detail the nature of Indian Bulk Drug Industry with an overview of the bulk drug industry, therapeutic segmentation and contract manufacturing.
• This report discusses in detail the nature of the Indian pharmaceutical market, market size, exports, imports and future outlook for the market.
• This report also analyses the critical success factors driving the industry as well as issues and challenges faced by the industry, like competition from China and excess capacity.
• Twenty major Indian companies have been profiled, covering aspects like products, key people, and financials for the last two years, key Strategies, DMF filings and future outlook for the company.
• Government regulations governing bulk drugs have been covered, along with details on production and pricing of bulk drugs.
• The report analyse the future outlook for the industry for the next three years, covering market size, exports and imports.
• Detailed lists of API manufacturers, Industry associations as well as key contacts are also covered in the report.

The report will be useful to

• Pharmaceutical companies,
• Pharmaceutical Exporters and importers
• Banks & investors.
• The educational institutes
• Government departments,
• Research bodies,
• Industry experts,
• Associations & consortia
• Consulting organizations.

Content